GlassScriptPhysician profile
Amy M Liss
NPI 1407360308
$8,297.49
in general payments reported to CMS, 2019-2025
28 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,168 · 2022: $3,317 · 2023: $1,489 · 2024: $666 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,718 · Education: $94.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.20 |
| Education | $94.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $2,218.04 | 2022 | |
| Nestle Healthcare Nutrition INC. | $2,009.62 | 2021-2023 | |
| Abbvie INC. | $1,186.66 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $487.89 | 2021-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $336.82 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $260.71 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Conmed Corporation | $188.02 | 2024-2025 | Conmed Hemostasis, Conmed Biliary |
| Phathom Pharmaceuticals, INC. | $187.58 | 2024-2025 | Voquezna |
| Pfizer INC. | $182.21 | 2023-2025 | |
| Qol Medical, LLC | $180.18 | 2023-2025 | Sucraid, Sucraid |
| Vivus LLC | $147.06 | 2021-2025 | Pancreaze |
| Takeda Pharmaceuticals U.S.A., INC. | $144.65 | 2023-2025 | Entyvio, Cuvitru, Eohilia |
| Intuitive Surgical, INC. | $132.80 | 2025 | |
| Ambu INC. | $113.78 | 2023 | |
| Sandoz INC. | $67.67 | 2023-2024 | Hyrimoz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $61.27 | 2021 | |
| Evoke Pharma, INC. | $58.11 | 2021-2022 | |
| Medtronic, INC. | $50.26 | 2022-2025 | Interstim |
| Lilly USA, LLC | $49.93 | 2024 | Omvoh |
| Ardelyx, INC. | $42.76 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $36.48 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $34.92 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $33.79 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $21.79 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $20.99 | 2021 | |
| Braintree Laboratories, INC. | $16.65 | 2021 | |
| Celgene Corporation | $13.71 | 2022 | |
| Fresenius Kabi USA, LLC | $13.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Liss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.